Abstract Objective: To evaluate the early and intermediate outcome of a consecutive series of emergency endovascular aneurysm repairs (eEVAR) of computed tomography (CT)-verified infrarenal ruptured abdominal aortic aneurysm (rAAA) at a single tertiary referral centre. Methods: Prospectively collected data of patients operated between April 2000 and October 2007 were retrospectively reviewed and all their pre-, intra-and postoperative imaging were re-evaluated. Patient and procedural data were analysed using a Cox multiregression model. Results: Ninety patients (86% men, aged 76 (AE7) years), were identified and included in the analysis. Symptom duration was <3 h in 22% of patients, 3e24 h in 39% and >24 h in 39%. Mean aneurysmal diameter was 73 (AE14) mm. All patients were treated with the COOK Zenith â stent-graft (56% bi-iliac and 44% uni-iliac). Sixty-one percent were haemodynamically unstable on presentation, and 26% required an intra-operative aortic occlusion balloon to maintain haemodynamic stability.
Introduction
Despite advances in operative technique and perioperative care over the past 50 years, the results of emergency opensurgical repair (eOR) of ruptured abdominal aortic aneurysms (rAAA) remain dismal, with mortality rates in the 50% range. 1 Endovascular AAA repair (EVAR) was described in the early 1990s by Parodi et al. and Volodos et al. and brought aortic aneurysm repair into the age of minimally invasive surgery. 2, 3 The use of EVAR for ruptured and symptomatic aneurysms (elective EVAR, eEVAR) was described a few years later, 4, 5 and it is presently being promoted as the treatment of choice in the emergency setting. 6 A number of small series report mortality rates from 0% to 45% for eEVAR, 5,7e16 but a large variability, both in device selection and in different pathologies treated, makes results hard to interpret. Non-randomised studies comparing eEVAR to elective open repair (eOR) indicate a lower 30-day mortality for the former (0e34% vs. 0e54%), 7e27 but the number of eEVAR patients is small. The only prospective, randomised, controlled trial published had a 30-day mortality of 53% for both treatment modalities. 28 The present study aims to report the early and intermediate results of 90 consecutive eEVAR procedures from a single referral centre.
Material and Methods
All patients with a computed tomography (CT)-confirmed rAAA treated with eEVAR between April 2000 and October 2007 were included in this study. Pseudoaneurysms, symptomatic aneurysms without evidence of rupture as well as fenestrated and custom-made devices were excluded.
At our institution, all EVAR procedures are performed in a hybrid operating room. Dedicated endovascular ancillary staff is available at all times. Since eEVAR has been the treatment of choice for rAAA at our department since 2001, a vast majority of patients with rAAA are evaluated with CT upon clinical suspicion of aneurysm rupture.
Data were prospectively registered in a local database. For the purpose of the present study, all charts, CT scans and angiograms were re-evaluated and verified and additional end-points collected. Data were then retrospectively analysed. Mortality data were cross-referenced with the Swedish National Population Registry.
Haemodynamic instability was defined as loss of consciousness or systolic blood pressure < 80 mmHg before induction of anaesthesia. Permissive hypotension was used until exclusion of the aneurysm was achieved. Blood pressure was regarded as satisfactory as long as the patient remained conscious. 29 Symptom duration was defined as the time passed since presentation of first clinical sign of rupture (i.e., pain, loss of consciousness, etc.).
Only the commercially available bi-or uni-iliac Zenith â stent-grafts (Cook Inc., USA) were used. The indication for choosing a uni-iliac device was technical (e.g., unilateral iliac occlusion or extreme tortuosity), clinical (extreme urgency) or logistical (appropriate bi-iliac system not available). Patients treated with an aorto-uni-iliac device also received a femoro-femoral bypass. Fig. 1 ) was inserted transfemorally and inflated in the supra-visceral aorta, as previously described in detail. 29 The follow-up consisted of clinical examinations, contrast-enhanced CT scans and plain abdominal radiographs at 1 and 12 months, and then annually for the remaining lifetime of the patient.
Morphological data were captured from thin-slice CT scans (mostly 0.75e3 mm) performed with and without intravenous contrast. Care was taken to locate the most orthogonal projection to measure the shortest axial vessel diameter to avoid overestimation of vessel size due to tortuosity.
The local ethics committee at Lund University approved the study.
All continuous variables were normally distributed, except for the data regarding intensive care unit (ICU) and Figure 1 The use of intra-operative occlusion balloon 29 (Latex, large diameter occlusion balloon or Coda â balloon catheter, www.cookmedical.com), as illustrated above, due to severe preoperative haemodynamic instability was the only procedure-related variable that correlated significantly with the 30-day mortality (p Z 0.003, rr: 4.8, 95% CI: 1.7e13.0). hospital stay. Continuous data are presented as mean -AE standard deviation. Comparisons were performed with standard Student's t-test and the corresponding paired ttest when appropriate. Non-normally distributed data are presented as median and interquartile range. Binary data were compared using the Fischer's exact test. Cox multivariate regression analyses and KaplaneMeier for survival curves were performed. All tests were two sided; p-values < 0.05 were considered significant. The SPSS software, version 13.0, was used (www.spss.com).
Results
Ninety eEVAR procedures were identified and included in the analysis. Patient data, AAA morphology, procedural data, outcome and re-intervention rates are summarised in Tables 1e4. Thirty-two patients (36%) had proximal aneurysm necks 15 mm or shorter in length. No graft-related endoleaks (type 1 or 3) were left untreated.
None of the 90 eEVAR procedures was converted to open repair. The all-cause 30-day mortality was 27% (24/90). Six patients died perioperatively and another six within 24 h. The remaining 12 patients died within 30 days due to multiple organ failure (MOF) or myocardial infarction (MI). Table 1 shows the co-morbidities and risk factors of the patients. The patients had a mean of 4(AE2) co-morbidities and risk factors (Table 1) . No single patient was without any co-morbidities or risk factors. In a multivariate regression analysis testing the variables presented in Table 1 
Re-interventions
Twenty-four (27%) patients underwent re-interventions during follow-up (Table 4) . Eight open re-interventions were performed, all in the immediate postoperative phase. Seven of these underwent exploratory laparotomy for bowel ischaemia (n Z 3), abdominal compartment syndrome (n Z 3) or bleeding (n Z 1). Of these, only one survived more than 30 days. One patient underwent common femoral patch repair due to occlusion. Seven patients underwent endovascular re-intervention: six during late follow-up (two additional stenting of endograft limbs due to kink, two embolisations due to type-2 endoleaks and expanding aneurysms, two proximal Palmaz stent placement due to type-1 endoleak) and one early (diagnostic CO 2 angiography only) due to worsened renal function postoperatively. Nine patients underwent combined open and endovascular re-interventions postoperatively: six in the acute phase (two diagnostic angiography and exploratory laparotomy due to haemodynamic instability, both negative; two superior mesenteric artery (SMA) stenting and bowel resection due to iatrogenic SMA coverage by the aortic stent-graft e both died in hospital; one iliac stent-graft and femoral interposition graft due to external iliac artery rupture; one iliac stenting, open balloon embolectomy and fasciotomy due to stent-graft limb occlusion) and three in the late phase (one fenestrated Table 1 The coronary co-morbidity was defined as angina pectoris, history of myocardial infarction, medication to prevent or treat these conditions or previous re-vascularisation. Diabetes includes both insulin-or non-insulindependent disease. Haemodynamic instability was defined as loss of consciousness or recorded blood pressure < 80 mmHg at any time preoperatively. The value of the preoperative haemoglobin concentration did not take into account the duration of symptoms or any intravenous fluid given before the intervention. Cerebrovascular disease and COPD correlated significantly to the 30-day mortality (p Z 0.007, rr: 3.8, 95% CI: 1.4e10. 5 The mean clinical follow-up was 27 months (AE18) and the mean CT follow-up was 24 months (AE15). No patient was lost to follow-up.
The cumulative survival data are presented in Fig. 2 . The 1-year all-cause mortality was 37% (33 patients). Nine patients died between the 2nd and 12th month. Six of the deaths were related to the procedure and included MOF (two), sepsis (one), MI (one), heart failure (one) and renal failure (one). Three deaths were unrelated to the rAAA (two malignancies and one gastroenteritis). Hence, the 1-year aneurysm-related death rate was 33% (30 of 90 cases). The 3-year survival rate was 50%.
Discussion
The majority of patients with rAAA die before reaching the hospital, and it is estimated that only 10% reach the operating room alive. 31 Despite advances in open-surgical repair and preoperative care, the mortality for open repair of rAAA remains between 45% and 50%. 1 The massive surgical trauma to the already massively traumatised patient with an rAAA is a lethal combination. The theoretical advantages to an endovascular approach are manifold. eEVAR can be performed percutaneously under local anaesthesia, thus avoiding the vasodilating and negatively inotropic effects of general anaesthesia. Transfemoral access avoids the devastating effects of a large, midline laparotomy on muscle wall tone, which can lead to further circulatory compromise. In addition, surgical dissection in the setting of a large retroperitoneal haematoma is avoided and blood loss is minimised. Lastly, EVAR also allows for continuous aortic flow, avoiding the effects of aortic cross-clamping with potential reperfusion injury. The potential downsides of eEVAR include technical, anatomical and logistical issues. A preoperative CT is preferred, if not mandatory, and can cause unnecessary delay in treatment. Several studies, however, indicate that this plays a much lesser role for the outcome of these patients than previously believed. EVAR is also presently limited to patients with suitable aneurysm necks and adequate access, and this will preclude a number of patients from an endovascular option if strict criteria are used for inclusion. Logistically, the need for appropriate intra-operative imaging, fully trained staff as well as the availability of correct endograft inventory also limits the widespread use of the technique. Our data, with a 30-day mortality of 27%, correspond well to the previously published smaller series with respect to patient-, aneurysm-, procedure-and outcome/complication-related data. Furthermore, they correspond to the recent meta-analyses by Lovegrove et al. of 463 patients treated with eEVAR for rAAA. 32 This is somewhat surprising considering the very high rate of haemodynamically unstable patients (61%) reflected in the high use of aortic occlusion balloon (26%), in which the outcome proved to be the worst. These acceptable results in the face of a high proportion of unstable patients might be due to selection bias and the fact that the report is not an intention-to-treat analysis and can only be validated with further studies.
The limitations of the present series are inherent to single-centre retrospective reports and, therefore, any attempt at generalisation must be undertaken with caution. In addition, no comparison to eOR under the same study period was made. During the study period, there has been a gradual shift towards eEVAR as presented earlier, 24 and currently the amount of eEVAR by far exceeds eOR. Therefore, any comparison may be unjust. Furthermore, the precise number of rAAA patients, where no attempt at repair, open or endovascular, was made is not known. It might be argued that since we perceive eEVAR to be less traumatic for patients with rAAA, we apply it more liberally than we would with open repair. This will potentially affect results negatively if older, sicker patients are treated and thus produce worse outcome for EVAR than if stricter inclusion criteria were applied. Conversely, the morphological and logistical issues might, in some cases, disqualify patients for EVAR, forcing the unsuitable patients to undergo open repair, perhaps thereby negatively affecting the outcome for this group. Obviously, these issues can be resolved only if randomised studies are undertaken. There are, however, ethical issues being raised regarding a randomised trial. If the results of EVAR were truly as good as have been indicated in some studies and the results of OR are quite stable and with mortality rates of 40e50%, would it be ethically responsible to randomise patients? Ultimately, this decision remains with the individual physician or perhaps the institution that has to scrutinise his/her/its own experience and the setting in which treatment is offered.
Questions regarding the general applicability of eEVAR compared to eOR have been raised, indicating that if strict criteria for eEVAR are applied, only a minority of patients can be treated. Accepting wider inclusion criteria (shorter, wider necks or access problems) might negatively affect the durability of the procedure. One must keep in perspective, however, that the aim of elective versus emergency treatment is quite different. In the former, a good short-term outcome is guaranteed for most, and thus long-term durability becomes paramount. In the latter, short-term outcome is more uncertain and thus tips the scale towards making this much more vital for the choice of repair. Consequently, the role of eEVAR and its ability to reduce immediate mortality speaks in its favour. Neither the question of applicability or durability (as indicated by secondary interventions) was specifically addressed in this series. However, others have looked into the matter. The overall applicability of eEVAR was approximately only 30% of rAAA cases in one study. 33 We estimate that our applicability is considerably higher, mainly due to a more favourable logistical setting and a more aggressive approach. The rate of re-intervention in our study was numerically (28%) higher compared to other reports, where this parameter was the main end-point of the study. 15 This may, at least, be partly due to the policy of having eEVAR as the first line of treatment of rAAA at our department, thus accepting anatomical and clinical parameters that will likely affect durability negatively.
Regardless of which modality is used to treat these very ill patients, it is unlikely that the long-term all-cause mortality will differ substantially as indicated in the randomised trials of elective EVAR 34, 35 as well as the results in the present study with a 50% survival rate 3 years after the procedure. In the shorter perspective, it may even be likely that the early and intermediate results of eEVAR will be less favourable as more and more difficult cases are being attempted. The future will probably reveal a final, appropriate equilibrium between eOR and eEVAR.
We believe that the favourable outcome in this large consecutive series of eEVAR may be attributed to several reasons. Firstly, the endovascular specialists, the vascular surgeons and the properly trained ancillary staff have worked together for a long time as 'one' team, accumulating a vast collective experience in the elective setting. Secondly, the in-house logistics allow us to evaluate every patient for a possible eEVAR with a CT at all times. Thirdly, we have deliberately chosen to use only one type of modular stentgraft system (Cook Zenith â system), thus allowing the entire Figure 2 The cumulative survival (KaplaneMeier) for allcause mortality after 30 days and 1 year was 73% and 63%, respectively. The causes of death within the first month were either multiple organ failure or myocardial/vascular. Two out of three deaths that occurred between the 2nd and the 12th month were aneurysm related. After 3 years, only half the number of patients were alive.
team to become accustomed to a single device. The system is commercially available and we find it versatile in almost cases, as demonstrated by the 100% technical success rate in excluding the rAAA in the acute phase. It seems logical that in light of these and other cautiously promising results, the increasing number of elective EVARs with the parallel technical development of both the stent-graft design/delivery and imaging will further increase the use of eEVAR over eOR. Further studies will determine the ultimate role of eEVAR versus eOR.
